Fixed-dose combination in pulmonology


Authors: V. Kašák
Authors‘ workplace: Oddělení respiračních nemocí, LERYMED spol. s r. o., Praha
Published in: Kardiol Rev Int Med 2016, 18(2): 115-118

Overview

Pharmacotherapy is one of the cornerstones of the treatment for patients with chronic bronchial obstruction – CBO, including asthma, chronic obstructive pulmonary disease (COPD) and the overlap of asthma and COPD syndrome (ACOS). The overview article discusses the role of traditional fixed-dose combination therapy, i.e. inhaled corticosteroid (IKS) plus a long-acting β2-agonist (LABA) or ultra-long-acting β2-agonist (U-LABA) and novel fixed-dose dual bronchodilators for maintenance treatment of COPD. Furthermore, the inhaled route is the first-choice administration method in the management of CBO. Inhaled medications for CBO are available in different devices with different characteristics and inhalation techniques. Therefore it is very important to continuously educate the patients on the correct inhalation technique.

Keywords:
pharmacotherapy of CBO – COPD – asthma – fixed-dose combination – fixed-dose dual bronchodilators therapy


Sources

1. Kašáková E, Kašák V. Může nesprávná inhalační technika ovlivnit efektivitu léčby pa­cientů s chronickou bronchiální obstrukcí? Alergie 2015; 17: 39– 44.

2. Teřl M. Inhalační léčba astmatu –  cesta do průdušek i duše pa­cienta. Alergie 2015; 17: 33– 36.

3. Koblížek V, Chlumský J, Zindr V et al. Doporučený postup ČPFS pro dia­gnostiku a léčbu stabilní CHOPN. Praha: Maxdorf Jessenius 2013.

4. Teřl M, Čáp P, Dvořáková R et al. Doporučený postup dia­gnostiky a léčby bronchiálního astmatu. Semily: GEUM 2015.

5. Global strategy for the dia­gnosis, management and prevention of chronic obstructive lung dis­ease. Updated 2016. GOLD 2016. Available from: http:/ / www.goldcopd.com.

6. Global strategy for asthma management and prevention. Revised 2016. GINA 2016. Available from: http:/ / www.ginasthma.org.

7. Barnes PJ. Scientific rationale for inhaled combination therapy with long-acting β2-agonists and corticosteroids. Eur Respir J 2002; 19: 182– 191.

8. Bateman ED, Mahler DA, Vogelmeier CF et al. Recent advances in COPD disease management with fix dose long-acting combination ther­apies. Expert Rev Respir Med 2014; 8: 357– 379. do­i: 10.1586/ 17476348.2014.910457.

9. Kašák V. Farmakoterapie CHOPN v roce 2015. Postgrad Med 2015; 17 (Příloha 1): 16– 22.

10. Cazzola M, Page CP, Calzeta L et al. Pharmacology and therapeutics of bronchodilators. Pharmacol Rev 2012; 64: 450– 504. doi: 10.1124/ pr.111.004580.

11. Barjaktarevic IZ, Arrendondo AF, Cooper CB. Positioning new pharmacotherapies for COPD. Int J Cron Obstruct Pulmon Dis 2015; 10: 1427– 1442. doi: 10.2147/ COPD.S83758.

12. Kašák V. Indacaterol/ glykopyrronium bromid –  první fixní kombinace s dlouhodobým duálním bronchodilatačním účinkem. Farmakoterapie 2014; 10: 436– 447.

13. Kudela O, Sedlák V, Koblížek V. Duální bronchodilatační léčba. Acta Medicinae 2015; 10: 44– 46.

14. Kašák V. Nové léky pro léčbu astmatu a CHOPN na našem farmaceutickém trhu. Alergie 2015; 17: 183– 190.

15. Marel M. Nová léková kombinace Relvar Ellipta pro nemocné s CHOPN a s bronchiálním astmatem. Studia Pneumol Phtiseol 2014; 74: 194– 200.

16. Marel M. Nová duální kombinace aclidinium bromidu a formoterol v léčbě nemocných s chronickou obstrukční plicní nemocí. Farmakoterapie 2015; 11: 492– 503.

17. Pauk N. Fixní kombinace aclidinium bromid/ formoterol fumarát –  vhodná duální bronchodilatační léčba CHOPN. Stud Pneumol Phtiseol 2015; 75: 131– 135.

Labels
Paediatric cardiology Cardiac surgery Cardiology
Login
Forgotten password

Don‘t have an account?  Create new account

Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account